Bone Abstracts

Young transsexuals at a minimum age of 12 years are treated with GnRH-analogues (GnRHa) to suspend pubertal development until the addition of hormones of the desired sex is started at a minimum age of 16 years. The effect of this treatment on adult bone mineral density (BMD) is still unknown. We aimed to assess BMD at the age of 22, as this is near its peak in healthy individuals.In this prospective observational study 19 female to male (FtM) and 16 male...

Background: Puberty is highly important for the accumulation of bone mass. Bone turnover and bone mineral density can be affected in transgender adolescents when puberty is postponed by gonadotropin-releasing hormone analogues (GnRHa), followed by treatment with cross-sex hormone therapy (CSHT).Objective: To investigate the effect of GnRHa and CSHT on bone turnover markers (BTMs) and bone mineral apparent density (BMAD) in transgender adolescents.<p ...